Newer respiratory virus infections: Human metapneumovirus, avian influenza virus, and human coronaviruses

Current Opinion in Infectious Diseases

Volumn 18, Issue 2, 2005, Pages 141-146

  Fouchier, Ron A M ^a   Rimmelzwaan, Guus F ^a   Kuiken, Thijs ^a   Osterhaus, Albert D M E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Coronavirus; Influenza a virus; Metapneumovirus; Respiratory disease

Indexed keywords

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIGENICITY; AVIAN INFLUENZA; CORONAVIRUS; DIAGNOSTIC TEST; GENETIC VARIABILITY; HUMAN; HUMAN METAPNEUMOVIRUS; INFLUENZA VIRUS; PATHOGENESIS; RESPIRATORY TRACT INFECTION; REVIEW; VIRUS DETECTION; VIRUS IDENTIFICATION; VIRUS TRANSMISSION; ZOONOSIS;

EID: 15044362191     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000160903.56566.84     Document Type: Review

References (80)

1. Bertino JS. Cost burden of viral respiratory infection: issues for formulary decision makers. Am J Med 2002; 112:42S-49S.
2. Monto AS, Sullivan KM. Acute respiratory illness in the community: frequency of illness and the agents involved. Epidemiol Infect 1993; 110:145-160.
3. van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001; 7:719-724.
4. van den Hoogen BG, Osterhaus DM, Fouchier RA. Clinical impact and diagnosis of human metapneumovirus infection. Pediatr Infect Dis J 2004; 23:S25-S32.
5. Kahn JS. Human metapneumovirus: a newly emerging respiratory pathogen. Curr Opin Infect Dis 2003; 16:255-258.
6. Williams JV, Harris PA, Tollefson SJ, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med 2004; 350:443-450. Twenty-five-year follow-up study on hMPV in children. hMPV was detected in 12 and 15% of children with lower and upper RTI, respectively. Detailed information on clinical features, reinfections, and genetic variability of hMPV are provided.
7. van den Hoogen BG, van Doornum GJ, Fockens JC, et al. Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients. J Infect Dis 2003; 188:1571-1577. Testing of all patients with RTI during two winter seasons in a Dutch Academic hospital. Symptoms of children infected with RSV and hMPV are compared.
8. Mullins JA, Erdman DD, Weinberg GA, et al. Human metapneumovirus infection among children hospitalized with acute respiratory illness. Emerg Infect Dis 2004; 10:700-705. One-year study in children in the US, comparing the prevalence of hMPV with other virus infections, and providing information on demography and symptoms.
9. Laham FR, Israele V, Casellas JM, et al. Differential production of inflammatory cytokines in primary infection with human metapneumovirus and with other common respiratory viruses of infancy. J Infect Dis 2004; 189:2047-2056. Study describing the prevalence of hMPV in Argentina, and comparison of inflammatory cytokine responses due to various virus infections.
10. Dollner H, Risnes K, Radtke A, Nordbo SA. Outbreak of human metapneumovirus infection in Norwegian children. Pediatr Infect Dis J 2004; 23:436-440. Description of a winter epidemic with high prevalence of hMPV, and many children presenting with severe disease.
11. McAdam AJ, Hasenbein ME, Feldman HA, et al. Human metapneumovirus in children tested at a tertiary-care hospital. J Infect Dis 2004; 190:20-26. Two-year study on prevalence of hMPV, also providing information on seasonally and underlying disease of the infected children.
12. Esper F, Martinello RA, Boucher D, et al. A 1-year experience with human metapneumovirus in children aged <5 years. J Infect Dis 2004; 189:1388-1396. Detection of hMPV in 8% of children with RTI negative for other viruses and description of clinical features. Information on genetic variation of hMPV is also provided.
13. Greensill J, McNamara PS, Dove W, et al. Human metapneumovirus in severe respiratory syncytial virus bronchiolitis. Emerg Infect Dis 2003; 9:372-375.
14. Konig B, Konig W, Arnold R, et al. Prospective study of human metapneumovirus infection in children less than 3 years of age. J Clin Microbiol 2004; 42:4632-4635. Population-based study in Germany focusing on RSV-hMPV double infections.
15. Cuevas LE, Nasser AM, Dove W, et al. Human metapneumovirus and respiratory syncytial virus. Brazil Emerg Infect Dis 2003; 9:1626-1628. Study on clinical symptoms associated with infections by hMPV, RSV, or both in Brazil.
16. Freymouth F, Vabret A, Legrand L, et al. Presence of the new human metapneumovirus in French children with bronchiolitis. Pediatr Infect Dis J 2003; 22:92-94.
17. Peiris JS, Tang WH, Chan KH, et al. Children with respiratory disease associated with metapneumovirus in Hong Kong. Emerg Infect Dis 2003; 9:628-633.
18. von Linstow ML, Henrik Larsen H, Eugen-Olsen J, et al. Human metapneumovirus and respiratory syncytial virus in hospitalized Danish children with acute respiratory tract infection. Scand J Infect Dis 2004; 36:578-584.
19. Rawlinson WD, Waliuzzaman Z, Carter IW, et al. Asthma exacerbations in children associated with rhinovirus but not human metapneumovirus infection. J Infect Dis 2003; 187:1314-1318.
20. Falsey AR, Erdman D, Anderson LJ, Walsh EE. Human metapneumovirus infections in young and elderly adults. J Infect Dis 2003; 187:785-790.
21. Bastien N, Ward D, Van Caeseele P, et al. Human metapneumovirus infection in the Canadian population. J Clin Microbiol 2003; 41:4642-4646.
22. Vicente D, Montes M, Cilla G, Perez-Trallero E. Human metapneumovirus and chronic obstructive pulmonary disease. Emerg Infect Dis 2004; 10:1338-1339.
23. van den Hoogen BG, Herfst S, Sprang L, et al. Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis 2004; 10:658-666. Study describing two serotypes of hMPV using ferret antisera, and four genetic lineages of hMPV based on the F and G genes.
24. Bastien N, Liu L, Ward D, et al. Genetic variability of the G glycoprotein gene of human metapneumovirus. J Clin Microbiol 2004; 42:3532-3537. Study describing antigenic variation of hMPV, and the genetic variation of the G gene of Canadian hMPV isolates.
25. van den Hoogen BG, Bestebroer TM, Osterhaus AD, Fouchier RA. Analysis of the genomic sequence of a human metapneumovirus. Virology 2002; 295:119-132.
26. Herfst S, de Graaf M, Schickli JH, et al. Recovery of human metapneumovirus genetic lineages a and B from cloned cDNA. J Virol 2004; 78:8264-8270. Minigenome reporter assays and techniques for recombinant virus production for both hMPV serotypes.
27. Biacohesi S, Skiadopoulos MH, Boivin G, et al. Genetic diversity between human metapneumovirus subgroups. Virology 2003; 315:1-9.
28. Skiadopoulos MH, Biacchesi S, Buchholz UJ, et al. The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J Virol 2004; 78:6927-6937. Comparison of hMPV replication in a variety of animal models, and evidence that the F gene is sufficiently conserved to confer protection against genetically diverse hMPVs.
29. MacPhail M, Schickli JH, Tang RS, et al. Identification of small-animal and primate models for evaluation of vaccine candidates for human metapneumovirus (hMPV) and implications for hMPV vaccine design. J Gen Virol 2004; 85:1655-1663. Comparison of hMPV replication in a variety of animal models, and evidence that genetically distinct hMPVs can provide cross-protective immunity despite antigenic differences.
30. Ebihara T, Endo R, Kikuta H, et al. Human metapneumovirus infection in Japanese children. J Clin Microbiol 2004; 42:126-132. This study describes the prevalence of hMPV and clinical symptoms in Japan, and provides information on the duration of virus shedding, and the occurrence of reinfections based on serological evidence.
31. Pelletier G, Dery P, Abed Y, Boivin G. Respiratory tract reinfections by the new human metapneumovirus in an immunocompromised child. Emerg Infect Dis 2002; 8:976-978.
32. Maertzdorf J, Wang CK, Brown JB, et al. Real-time reverse transcriptase PCR assay for detection of human metapneumoviruses from all known genetic lineages. J Clin Microbiol 2004; 42:981 -986. Conventional and real-time diagnostic polymerase chain reaction assays designed to detect the known genetic lineages of hMPV.
33. Tang RS, Schickli JH, MacPhail M, et al. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3′ proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. J Virol 2003; 77:10819-10828. Design of parainfluenza virus type 3-vectored hMPV and RSV vaccine candidates and evaluation in hamsters.
34. Schildgen O, Geikowski T, Glatzel T, et al. New variant of the human metapneumovirus (HMPV) associated with an acute and severe exacerbation of asthma bronchiale. J Clin Virol 2004; 31:283-288.
35. Kuiken T, van den Hoogen BG, van Riel DA, et al. Experimental human metapneumovirus infection of cynomolgus macaques (Macaca fascicularis) results in virus replication in ciliated epithelial cells and pneumocytes with associated lesions throughout the respiratory tract. Am J Pathol 2004; 164:1893-1900. Virology and pathology features of hMPV infection of macaques.
36. Tang RS, Mahmood K, MacPhail M, et al. A host-range restricted parainfluenza virus type 3 (PIV 3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys. Vaccine (in press).
37. Biacchesi S, Skiadopoulos MH, Tran KC, et al. Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes. Virology 2004; 321:247-259. Production of recombinant hMPV with or without insertion of heterologous genes.
38. Naylor CJ, Brown PA, Edworthy N, et al. Development of a reverse-genetics system for Avian pneumovirus demonstrates that the small hydrophobic (SH) and attachment (G) genes are not essential for virus viability. J Gen Virol 2004; 85:3219-3227.
39. de Jong JC, Claas EC, Osterhaus AD, et al. A pandemic warning? Nature 1997; 389:554.
40. Claas EC, Osterhaus AD, van Beek R, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998; 351:472-477.
41. Subbarao K, Klimov A, Katz J, et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998; 279:393-396.
42. Peiris JS, Yu WC, Leung CW, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004; 363:617-619. Clinical description and inflammatory cytokine responses in H5N1-infected patients in Hong Kong.
43. Guan Y, Poon LL, Cheung CY, et al. H5N1 influenza: a protean pandemic threat. Proc Natl Acad Sci U S A 2004; 101:8156-8161. Genotypic and phenoiypic characterization of H5N1 isolates obtained from humans in Hong Kong, and comparison with other H5N1 strains.
44. Avian influenza: South Korea (02). OIE; 13 December 2003. Archive number 20031213.3049. http://www.promedmail.org. [Accessed 1 November 2004].
45. Cumulative number of confirmed human cases of avian influenza A (H5N1) since 28 January 2004; 25 October 2004. http://www.who.int/csr/disease/ avian_influenza/country/cases_table_2004_10_25/en. [Accessed 1 November 2004].
46. Tran TH, Nguyen TL, Nguyen TD, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004; 350:1179-1188. Detailed description of 10 patients suffering from avian IAV infection, including eight fatal cases. The paper describes the clinical features, laboratory results, treatment and epidemiological data.
47. Grose C, Chokephaibulkit K. Avian influenza virus infection of children in Vietnam and Thailand. Pediatr Infect Dis J 2004; 23:793-794. Brief question and answer section on avian IAV (H5N1) in children.
48. Apisarnthanarak A, Kitphati R, Thongphubeth K, et al. Atypical avian influenza (H5N1). Emerg Infect Dis 2004; 10:1321-1324.
49. Avian influenza H5N1, mammals: East Asia; 21 February 2004. http:// www.promedmail.org. [Accessed 1 November 2004].
50. Keawcharoen J, Oraveerakul K, Kuiken T, et al. Avian influenza H5N1 in tigers and leopards. Emerg Infect Dis 2004; 10:2189-2191.
51. Kuiken T, Rimmelzwaan G, van Riel D, et al. Avian H5N1 influenza in cats. Science 2004; 306:241. Formal proof that H5N1 IAV can infect and cause disease in domestic cats.
52. Avian influenza, porcine, H5N1: China (06). OIE; 5 September 2004. http:// www.promedmail.org. [Accessed 1 November 2004].
53. Li KS, Guan Y, Wang J, et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004; 430:209-213. Detailed analysis of the genome composition of H5N1 IAVs in Southeast Asia from 1997 until 2004. The paper suggests that H5N1 strains have continued to circulate in ducks since 1997, and that ducks may be responsible for the widespread outbreak.
54. Chen H, Deng G, Li Z, et al. The evolution of H5N1 influenza viruses in ducks in southern China. Proc Natl Acad Sci U S A 2004; 101:10452-10457. Phenotype analyses of H5N1 strains isolated since 1996. The study shows that more recent strains acquired the ability to replicate in mice and cause systemic infection.
55. Sturm-Ramirez KM, Ellis T, Bousfield B, et al. Reemerging H5N1 influenza viruses in Hong Kong in 2002 are highly pathogenic to ducks. J Virol 2004; 78:4892-4901. Phenotype analyses of H5N1 strains isolated since 1996. The study shows differences in antigenic properties, and provides evidence that recent H5N1 strains are pathogenic to ducks.
56. Fouchier RA, Schneeberger PM, Rozendaal FW, et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A 2004; 101: 1356-1361. Analysis of viruses obtained during the Dutch H7N7 outbreak, including a description of the fatal case.
57. Koopmans M, Wilbrink B, Conyn M, et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004; 363:587-593. Epidemiological description of H7N7 infections of humans in The Netherlands and description of control measures.
58. Avian influenza H7N7, human: Netherlands 2003 (03); 15 October 2004. Archive number 20041015.2808. http://www.promedmail.org. [Accessed 1 November 2004].
59. Update: influenza activity: United States and worldwide, 2003-04 season, and composition of the 2004-05 influenza vaccine. MMWR Morb Mortal Wkly Rep 2004; 53:547-552.
60. Peiris M, Yuen KY, Leung CW, et al. Human infection with influenza H9N2. Lancet 1999; 354:916-917.
61. Choi YK, Ozaki H, Webby RJ, et al. Continuing evolution of H9N2 influenza viruses in Southeastern China. J Virol 2004; 78:8609-8614. Description of six genotypes of H9N2 IAVs circulating in Asia. All of these were able to replicate in chickens and mice, and some also in pigs.
62. Avian influenza A (H7N3) virus, human: Canada, BC (02); 2 April 2004. Archive number 20040402.0908. http://www.promedmail.org. [Accessed 1 November 2004].
63. Avian influenza A (H7N2) virus, human: New York 20 April 2004. Archive Number 20040420.1104. http://www.promedmail.org.
64. Avian influenza A (H1N7), humans, avians. Correction: Egypt; 24 May 2004. Archive Number 20040524.1393. http://www.promedmail.org. [Accessed 1 November 2004].
65. Webby RJ, Webster RG. Are we ready for pandemic influenza? Science 2003; 302:1519-1522. Authoritative review or pandemic preparedness. This paper summarizes recent progress with respect to preparation for the next influenza pandemic and, more importantly, highlights the most urgent needs.
66. Stohr K. The global agenda on influenza surveillance and control. Vaccine 2003; 21:1744-1748. This issue of the journal Vaccine is entirely dedicated to influenza vaccines, and Dr Stohr discusses the WHO Global Agenda on Influenza Surveillance and Control.
67. Stephenson I, Nicholson KG, Gluck R, et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/69 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003; 362:1959-1966. Comparison of two candidate pandemic vaccines in humans, revealing that whole virus vaccine was better than subunit vaccine. Two doses of either of the vaccines resulted in insufficient responses in naïve individuals.
68. Chen H, Subbarao K, Swayne D, et al. Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate. Vaccine 2003; 21:1974-1979. Production of a candidate pandemic vaccine based of classical reassortment and evaluation of pathogenicity in mice and chickens and protection in mice.
69. Webby RJ, Perez OR, Coleman JS, et al. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 2004; 363:1099-1103. Rapid production of a candidate pandemic vaccine based on reverse genetics technology, and evaluation of pathogenicity in chickens and ferrets.
70. Wood JM, Robertson JS. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol 2004; 2:842-847.
71. Stephenson I, Nicholson KG, Wood JM, et al. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 2004; 4:499-509. Excellent review on avian IAV infections of humans, experience with normal influenza vaccines, and limitations with candidate pandemic influenza vaccines.
72. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364:759-765. Study in Japanese children showing that upon use of the neuraminidase inhibitor oseltamivir, drug resistant viruses arise more frequently than previously reported.
73. Stevens J, Corper AL, Basler CF, et al. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 2004; 303:1866-1870. Structural analysis of the HA of Spanish Influenza virus revealing that many structural features are shared with avian rather than humar IAV HA, but the virus was still able to bind human receptors.
74. Gamblin SJ, Haire LF, Russell RJ, et al. The stucture and receptor binding properties of the 1918 influenza hemagglutinin. Science 2004: 303:1838-1842; See Stevens et al. [73].
75. Davidson A, Siddell S. Potential for antiviral treatment of severe acute respiratory syndrome. Curr Opin Infect Dis 2003; 16:565-571.
76. Wang JT, Chang SC. Severe acute respiratory syndrome. Curr Opin Infect Dis 2004; 17:143-148.
77. Poutanen SM, Low DE. Severe acute respiratory syndrome: an update. Curr Opin Infect Dis 2004; 17:287-294.
78. Fouchier RA, Hartwig NG, Bestebroer TM, et al. A previously undescribed coronavirus associated with respiratory disease in humans. Proc Natl Acad Sci U S A 2004 101:6212-6216. Discovery and genome sequence of HCoV-NL, and analysis of its prevalence in Rotterdam, The Netherlands.
79. van der Hoek L, Pyre K, Jebbink MF, et al. Identification of a new human coronavirus. Nat Med 2004; 10:368-373. Discovery and genome sequence of HCoV-NL63, and analysis of its prevalence in Amsterdam, The Netherlands.
80. Woo PC, Lau SK, Chu CM, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol (in press).